Juvenile idiopathic arthritis (JIA) and pediatric joint disorders
Nicolino Ruperto, MD, MPH
IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia
Genova, Genoa, Italy
Disclosure(s): Ablynx: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca-Medimmune: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bayer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Biogen: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb (BMS): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celgene: Grant/Research Support (Ongoing), Personal Fees, Non-Financial Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); EMD Serono: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); F. Hoffman-La Roche: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein (GSK): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck/MSD: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); R-Pharma: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sinergie: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sobi: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)
Stephen Balevic
Duke University
Durham, NC, United States
Disclosure(s): Purdue Pharma: Grant/Research Support (Terminated); UCB: Consultant (Ongoing)
As new targeted therapeutics are developed and approved in adults, studies to facilitate approval and access to these drugs are also needed for children with rheumatic diseases. These studies establish the correct dosing of medications and provide insight into the safety of their use. This session will review unique study design considerations for the pediatric population and discuss novel study designs that can facilitate more rapid approval and access to medications for children with rheumatic diseases.
Speaker: Nicolino Ruperto, MD, MPH – IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia
Virtual Speaker: Stephen Balevic – Duke University
